A
Description
Neuromodulation company founded in 2021, spin-out from the University of Oxford. Develops implantable adaptive neuromodulation therapies for high unmet clinical need. Lead device Amber-UI (Picostim™ system) targets the pudendal nerve to treat mixed urinary incontinence (MUI) in women. Results: 80% complete resolution in first-in-human studies. $100M funding raised.